4 Analysts Have This to Say About Moderna
Within the last quarter, Moderna (NASDAQ:MRNA) has observed the following analyst ratings:
Moderna To $165? Plus This Analyst Cuts PT On FedEx
Deutsche Bank raised the price target on Moderna, Inc. (NASDAQ: MRNA) from $155 to $165. Deutsche Bank analyst Emmanuel Papadakis also upgraded the stock from Hold to Buy. Moderna shares rose 2.8% to trade at $138.70 on Thursday.
Sanofi-GSK COVID-19 Vaccine May See European Approval Soon: Report
The European Union’s drugs regulator is just a few weeks away from deciding whether to approve Sanofi SA (NASDAQ:SNY) and GSK…
White House May Ask For $25B Emergency Funding For COVID-19, Monkeypox
The White House is seeking $44.5 billion in emergency funding from Congress for Covid-19 and monkeypox and back…
Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia Therapeutics’ (NASDAQ:NTLA) lead asset NTLA-2002,…
Europe Backs Approval Of Omicron-Adapted COVID-19 Vaccines
Health Canada has approved Moderna Inc's (NASDAQ: